P1/2, N=28, Active, not recruiting, University of Colorado, Denver | Trial primary completion date: Aug 2026 --> Oct 2025

Infiltrative mediastinal/retroperitoneal MS may present with esophageal obstruction and mimic lymphoma or carcinoma. High-index suspicion, targeted biopsy with high-power morphology, and a focused immunohistochemical panel are critical for timely diagnosis and treatment initiation.

The aim of the present study was to monitor the expression of Vim, ENO1, and their citrullinated forms (cit-Vim, cit-ENO1) during the regulation of spontaneous human neutrophil apoptosis (SA) by the antiapoptotic cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) and the proapoptotic anti-cancer drug arsenic trioxide (ATO)...However, Vim, ENO1, cit-Vim, and cit-ENO1 are expressed at the cell surface of apoptotic neutrophils. These data further support the potential participation of neutrophils in autoimmune and inflammatory diseases as they might be an important source of autoantigens when they undergo apoptosis.

The objective response rate (ORR) was significantly increased by Kanglaite injection (RR = 1.52, 95% confidence interval [CI]: 1.07-2.15, p = 0.02)...Due to limitations in the assessed research, high-quality clinical studies with rigorous designs are required to confirm the findings. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024561845, Identifier CRD42024561845.

P1, N=12, Not yet recruiting, Neonc Technologies, Inc. | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026

P2, N=30, Not yet recruiting, Sichuan University

P1, N=19, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 19 | Trial completion date: Mar 2043 --> Jul 2040 | Trial primary completion date: Mar 2027 --> Aug 2025

Compared to free ATO, the nanomedicine exhibited significantly improved in vivo anti-tumor effects, achieving a 100% 45-day survival rate in mice with favorable biosafety profiles. This study offers novel insights into tumor chemotherapy sensitization and presents a promising strategy for ATO nanoformulation development.

The effects of the SNHG26-CDKN2A axis on Cu + ELES(copper plus elesclomol)-induced cuproptosis and CD8+ T cell-mediated anti-tumour immunity were evaluated through cell viability, apoptosis, co-culture cytotoxicity and migration assays...Our findings reveal a novel regulatory axis whereby SNHG26 promotes CRC progression by destabilising CDKN2A mRNA, resulting in enhanced cell proliferation, cuproptosis and immune evasion. This study provides new insights into the molecular mechanisms underlying CRC development.

A cigarette compound-formed tumor microenvironment resisted HCC to sorafenib by locking the adaptor protein 14-3-3η in a constitutively active state. This outcome provided a mechanistic rationale and a translational strategy to re-sensitize HCC patients exposed to cigarette to targeted therapy.

In vivo experiments revealed that ES inhibited tumor growth and upregulated PCK2. Taking together, our findings reveal that the ES-ER stress-PCK2 axis is a critical mediator of copper-induced metabolic disruption, providing a rationale for targeting cuproptosis pathways in LUAD therapy.

In vitro experiments, the combination of elesclomol (a copper ion carrier) and bortezomib (Bortezomib) demonstrated a synergistic anti-myeloma effect through excessive intracellular reactive oxygen species generation. This study provides valuable insights into the role of CRGs in MM, potentially aiding in prognosis prediction and the development of effective, personalized therapeutic strategies.